Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
lung cancer
Advertisement
Eli Lilly to Present New Cardiometabolic Data at EASD 2026
Indianapolis, Indiana, September 15, 2026 Eli Lilly and Company will present new clinical and scientific data for Foundayo (orforglipron),...
Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer
Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...
J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
GSK’s Jideytro Shows 94% Response in ROS1 Lung Cancer
London, United Kingdom, September 13, 2026 GSK has announced positive registrational data from the Phase I/II ARROS-1 trial supporting...
Advertisements
AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Bayer Wins FDA Accelerated Approval for Sevabertinib
BERLIN — September 9, 2026 Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
Amgen and AstraZeneca’s IMDELLTRA-IMFINZI Improves SCLC Survival
Thousand Oaks, California, USA, September 8, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3 DeLLphi-305...
Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
Revolution Medicines Reports NEJM Data for RASONQUE in NSCLC
REDWOOD CITY, Calif., Sept. 2, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a commercial-stage oncology company focused on RAS-driven cancers,...
Advertisement
